Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Kathryn Horwitz to Dose-Response Relationship, Drug

This is a "connection" page, showing publications Kathryn Horwitz has written about Dose-Response Relationship, Drug.

 
Connection Strength
 
 
 
0.061
 
  1. Lange CA, Richer JK, Horwitz KB. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol. 1999 Jun; 13(6):829-36.
    View in: PubMed
    Score: 0.028
  2. Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol. 2005 Dec; 97(4):328-41.
    View in: PubMed
    Score: 0.011
  3. Pahl PM, Horwitz MA, Horwitz KB, Horwitz LD. Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. Breast Cancer Res Treat. 2001 Sep; 69(1):69-79.
    View in: PubMed
    Score: 0.008
  4. Horwitz KB, McGuire WL. Studies on mechanisms of estrogen and antiestrogen action in human breast cancer. Recent Results Cancer Res. 1980; 71:45-58.
    View in: PubMed
    Score: 0.007
  5. Horwitz KB, McGuire WL. Actinomycin D prevents nuclear processing of estrogen receptor. J Biol Chem. 1978 Sep 25; 253(18):6319-22.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)